Rankings
▼
Calendar
INMB Q1 2021 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena
INMB
INmune Bio, Inc.
$37M
Q1 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$4,000
Gross Profit
$4,000
100.0% margin
Operating Income
-$5M
-113700.0% margin
Net Income
-$5M
-113900.0% margin
EPS (Diluted)
$-0.32
QoQ Revenue Growth
-63.6%
Cash Flow
Operating Cash Flow
-$5M
Free Cash Flow
-$5M
Stock-Based Comp.
$899,000
Balance Sheet
Total Assets
$66M
Total Liabilities
$2M
Stockholders' Equity
$64M
Cash & Equivalents
$45M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4,000
$0
—
Gross Profit
$4,000
$0
—
Operating Income
-$5M
-$2M
-117.4%
Net Income
-$5M
-$2M
-120.1%
← FY 2021
All Quarters
Q2 2021 →